Skip to content
AkademScholar

Products

For developers

AkademBasesoonDeveloper API
Journal

Clinical & Translational Oncology

ISSN:
1699-048X
1
h-index
5
Citations
9
Works
1.00
2-year mean citedness

Trust signals

1 of 3 signals present

Independent positive signals — not a single “predatory/legitimate” verdict, but a converging picture.

  • DOAJ
    No data
    doaj.org
  • OAK list
    No data
    OAK
  • Valid ISSN
    Present
    ISSN

This is an information label, not an official ruling. A missing signal is not a penalty — a regional journal may simply not be in DOAJ.

Trends over time

Performance over time

Citation overview

Publications (bars) and citations (line) by year

  • Publications
  • Citations
03581001345202520262025: Publications 2, Citations 12026: Publications 7, Citations 4

Citation history

01345202520262025: Citations 12026: Citations 4

Publication history

035810202520262025: Publications 22026: Publications 7

h-index evolution

Cumulative h-index by year

01202520262025: h-index 12026: h-index 1

Most-cited works

  1. Circulating tumor DNA as a predictive biomarker for colorectal cancer postsurgical recurrence: a systematic review and meta-analysis20252 citations
  2. Emerging strategies to reduce the side effects of CAR-T cell therapy: focusing on gene editing and nanotechnology20261 citations
  3. The evolution of cellular-based immunotherapy in the treatment of gastric cancer: an overview of clinical trials20261 citations
  4. Prognostic value of postoperative circulating tumor DNA for recurrence-free survival in resected non-small cell lung cancer: a systematic review and meta-analysis20251 citations
  5. CTLA-4: a promising immunosuppressive immune checkpoint in prostate cancer therapy20260 citations
  6. Epigenetic insights and innovations for overcoming barriers in CAR-T cell therapy for cancer20260 citations
  7. Circulating tumor DNA-based detection of molecular residual disease in isocitrate dehydrogenase-mutant cholangiocarcinoma for biomarker-guided therapy20260 citations
  8. CAR-engineered neutrophils derived from induced pluripotent stem cells: a new frontier in cellular immunotherapy20260 citations
  9. Trogocytosis in cancer immunity and cellular immunotherapy: mechanisms, therapeutic challenges, and translational opportunities20260 citations